Eight of the 30 Dow components lost value in 2024. Here's a quick look at each company, to help you determine which dividend ...

But the trial showed it achieved an average of 22.7% weight loss after more than a year's treatment, roughly in line with Eli Lilly's Zepbound, which is already available. Morningstar Research ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Treasury yields are getting cheaper and rate cut bets are back on the rise. The Dow Jones Industrial Average (DJIA) added over a full percentage point in value on Friday, climbing around 500 ...

Investors continue to hinge their exposure on Fed rate cut expectations. The Dow Jones Industrial Average (DJIA) struck a middling tone on Thursday, churning around the 43,200 handle and testing ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Futures on the Dow Jones Industrial Average rose Monday in electronic trade as the U.S. dollar slumped after a report that President-elect Donald Trump won’t impose new tariffs during his first ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Ich bin damit einverstanden, dass mir die BurdaForward GmbH, St. Martin Straße 66, 81541 München, regelmäßig News zu den oben ausgewählten Themenbereichen per E-Mail zusendet. Ich bin ...